eli lilly glp-1 agonist As Use Expands, Long-Term Safety Questions Remain Under Watch Eli Lilly releases topline data
Description
doi:10.1016/j.str.2021.04.001 33
Among the diverse array of antidiabetic agents, the class of GLP-1 receptor agonists has garnered substantial attention not only for their glycemic control properties but also for their potential cardiovascular benefits (35)
That may sound pie-in-the-sky, But everyone can live healthier lives which will make things better as a society.
Clinical evidence The effectiveness of combination therapy with PIO (1530 mg daily) and tofogliflozin (TOFO 20 mg daily) for 24 weeks was investigated in 32 patients who experienced T2D and NAFLD in an open-label RCT [116]
There are two main trials (FIGHT and LIVE trials) demonstrating that treatment with liraglutide increased the risk of adverse heart failure-associated outcomes in patients with heart failure and reduced LVEF [43-45]
GLP-1 receptor agonists are designed to resist rapid enzymatic degradation, thereby allowing sustained receptor activation
